News
Swiss breast cancer startup announces VA research collaboration

Swiss startup OncoGenomX, a leader in predictive tumour analytics, has announced a new clinical trial collaboration with researchers of two US Veterans Affairs (VA) Medical Centers.
The project will test OncoGenomX’s revolutionary clinical decision support platform PredictionStar™— created with the goal of making personalised precision cancer treatment a reality for all women living with breast cancer— within a hospital user environment.
It will focus on the treatment of early hormone receptor-positive breast cancer in patients eligible for post-operative therapy with Tamoxifen or a Non-steroidal aromatase inhibitor, and patients with metastatic hormone receptor-positive breast cancer eligible for therapy with Palbociclib (Pfizer), Alpelisib (Novartis), or Trastuzumab-Deruxtecan (AstraZeneca).
The results of the project, conducted with the VA Molecular Diagnostic Laboratory in Los Angeles and the Department of Pathology and Laboratory Medicine in Cincinnati, promise to enrich OncoGenomX’s existing knowledge base with critical insights.
By analysing a comprehensive range of patient and tumour specific data—including clinical, biological, pathological, phenotypic, genomic, transcriptomic, and proteomic— PredictionStar™ delivers a 360-degree characterisation of individual tumours. This enables clinicians to move beyond standard treatment protocols, which often result in over or under treatment, and instead make precise, evidence-based therapeutic decisions.
According to OncoGenomX’s research, 56% of women living with metastatic breast cancer are at risk of receiving suboptimal treatment compositions, leading to clinical outcomes falling short of the potential of modern breast cancer treatments, and causing avoidable cancer care costs.
PredictionStar™ reduces the risk of such outcomes, lowering the over treatment rate by at least 40% from 56% to 16% or less, incurring a five-fold lower risk of cancer regrowth, and 40% lower therapy success costs.
The VA collaboration will allow OncoGenomX to optimise the PredictionStarTM support platform based on user experience, to identify the parameters critical for maximum system performance, accurate pre-therapy outcome predictions, and reliable treatment guidance.
The study will compare PredictionStar™’s projected outcomes with actual patient results, ensuring the technology is effective in clinical settings beyond controlled studies.
“We expect this collaboration to enrich our existing knowledgebase, which already includes over 4,500 breast cancer cases,” says CEO Wolfgang Hackl.
“Real-world validation is crucial for generalising our findings and ensuring they reflect the reality in diverse healthcare environments.”
Stressing the importance of this, Dr Bernard L. Kasten, Principal Investigator at the Cincinnati VA Medical Center, adds: “Current biomarkers lack the sensitivity needed for precise pre-treatment predictions. PredictionStar™ fills this gap by offering detailed, objective insights into tumour biology, leading to more effective and personalised treatments.”
The opportunity for OncoGenomX—recently named Most Innovative Oncology Software Company at the GHP Awards—is substantial.
The collaboration will open doors to complement the company’s knowledge base and extend its claims with real-world data, which is essential for establishing broader clinical and financial support.
This research is just one part of the company’s broader mission, Hackl explains: “Our goal is to establish the first PredictionStar™ laboratory and build a robust development alliance with industry partners, academic institutions, and healthcare payers. We are taking significant steps toward making PredictionStar™ the standard for breast cancer treatment and extending it to other types of cancer and biomedical applications.”
He adds: “Our overarching aim is to make precision treatment matching with PredictionStar™ the norm in breast cancer care, and stepwise extending its application to other cancers.”
Diagnosis
AI may help accelerate breast cancer diagnosis for high-risk women – study
Fertility
Infertility may be risk factor for early menopause, study suggests
News
Endometriosis documentary profiles stars including Marilyn Monroe and Amy Schumer

A non-profit has launched an endometriosis documentary featuring Amy Schumer and Marilyn Monroe as it pushes for changes in how the condition is treated and understood.
The Endometriosis Collective has launched to change how endometriosis is researched, treated and understood, starting with a documentary featuring stories from people including Amy Schumer and Marilyn Monroe.
The feature-length documentary, “End of the Cycle”, will premiere in New York on Tuesday, and The Endometriosis Collective is making the film free to stream online.
Schumer, a comedian, writer and actor, has previously spoken of how endometriosis left her “on the floor in pain, vomiting from the pain, the pain that nobody can see.”
Schumer is one of several celebrities featured in the documentary. Other contributors include dancer Julianne Hough, Olympic medallist Brittany Brown and actors Janel Parrish and Folake Olowofoyeku.
The Endometriosis Collective timed the documentary premiere to coincide with the 100th anniversary of Marilyn Monroe’s birth.
Monroe, who died in 1962, starred in films such as “Some Like It Hot” and “Gentlemen Prefer Blondes.”
According to a biography published in 1985, Monroe’s endometriosis was so severe that it destroyed her marriages, her wish for children, her career and ultimately her life.
The Endometriosis Collective said the documentary shares newly uncovered information about Monroe’s experience with endometriosis.
The non-profit said the information connects Monroe’s story to the experiences of women across generations, highlighting how far awareness, research and care still have to go.
A representative of the Marilyn Monroe Estate said: “By sharing this part of her story through ‘End of the Cycle,’ we hope to honour her legacy in a way that brings visibility to endometriosis, encourages more open dialogue and helps inspire the research needed to create change.”
As part of the premiere, The Endometriosis Collective is holding a panel discussion.
Schumer, Brown and Olowofoyeku, the documentary’s co-directors Sammy Jaye and Soraya Simi, and medical experts are due to be part of the premiere.
AbbVie’s Orilissa and Sumitomo Pharma’s Myfembree are among the approved drugs for endometriosis pain.
Hough, one of the participants in the documentary, starred in an Orilissa campaign in 2017.
Menopause1 week agoPerimenopause misinformation ‘putting women at risk’
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Hormonal health2 weeks agoNHS urged to update website following renaming of PCOS
News6 days agoThree menopause innovators shortlisted for Femtech World Award















